Renaissance Technologies’s Lipocine LPCN Stock Holding History

Renaissance Technologies’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$308K	Buy	38,497 +1,100	+3%	+$9.58K	﹤0.01%	2784
2025 Q4	$300K	Buy	37,397 +1,300	+4%	+$4.37K	﹤0.01%	2761
2025 Q3	$103K	Buy	36,097 +1,300	+4%	+$3.95K	﹤0.01%	3246
2025 Q2	$110K	Sell	34,797 -2,713	-7%	-$8.8K	﹤0.01%	3286
2025 Q1	$119K	Buy	37,510 +1,478	+4%	+$5.72K	﹤0.01%	3165
2024 Q4	$176K	Sell	36,032 -4,300	-11%	-$21.8K	﹤0.01%	3198
2024 Q3	$181K	Buy	40,332 +14,635	+57%	+$73.5K	﹤0.01%	3144
2024 Q2	$212K	Buy	25,697 +4,600	+22%	+$28.8K	﹤0.01%	3027
2024 Q1	$110K	Buy	21,097 +2,300	+12%	+$8.95K	﹤0.01%	3352
2023 Q4	$52K	Buy	18,797 +3,200	+21%	+$8.46K	﹤0.01%	3448
2023 Q3	$46K	Buy	15,597 +5,200	+50%	+$21.9K	﹤0.01%	3416
2023 Q2	$52K	Sell	10,397 -1,271	-11%	-$5.98K	﹤0.01%	3609
2023 Q1	$63K	Buy	11,668 +121	+1%	+$935	﹤0.01%	3604
2022 Q4	$78K	Sell	11,547 -182	-2%	-$1.33K	﹤0.01%	3693
2022 Q3	$90K	Buy	11,729 +6,964	+146%	+$77.8K	﹤0.01%	3627
2022 Q2	$65K	Buy	4,765 +3,936	+475%	+$61.3K	﹤0.01%	3950
2022 Q1	$19K	Buy	+829	New	+$17.3K	﹤0.01%	4008
2020 Q3	–	Sell	-18,594	Closed	-$398K	–	3542
2020 Q2	$398K	Buy	18,594 +2,411	+15%	+$31.2K	﹤0.01%	2942
2020 Q1	$132K	Sell	16,183 -95,656	-86%	-$757K	﹤0.01%	3178
2019 Q4	$732K	Buy	111,839 +76,029	+212%	+$1.95M	﹤0.01%	2758
2019 Q3	$1.71M	Buy	35,810 +6,654	+23%	+$267K	﹤0.01%	2357
2019 Q2	$967K	Buy	29,156 +5,232	+22%	+$161K	﹤0.01%	2695
2019 Q1	$939K	Buy	23,924 +12,065	+102%	+$370K	﹤0.01%	2697
2018 Q4	$262K	Buy	11,859 +3,906	+49%	+$90.6K	﹤0.01%	3073
2018 Q3	$187K	Buy	7,953 +1,724	+28%	+$42.4K	﹤0.01%	3164
2018 Q2	$138K	Buy	6,229 +1,411	+29%	+$33.6K	﹤0.01%	3117
2018 Q1	$125K	Buy	+4,818	New	+$134K	﹤0.01%	3245
2017 Q4	–	Sell	-13,447	Closed	-$908K	–	3434
2017 Q3	$908K	Buy	+13,447	New	+$972K	﹤0.01%	2605
2016 Q2	–	Sell	-1,129	Closed	-$195K	–	3434
2016 Q1	$195K	Sell	1,129 -9,412	-89%	-$1.61M	﹤0.01%	3099
2015 Q4	$2.32M	Sell	10,541 -3,559	-25%	-$747K	0.01%	2009
2015 Q3	$2.84M	Buy	14,100 +3,285	+30%	+$760K	0.01%	1770
2015 Q2	$1.58M	Buy	10,815 +9,356	+641%	+$1.16M	﹤0.01%	2208
2015 Q1	$171K	Buy	+1,459	New	+$159K	﹤0.01%	2924

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Renaissance Technologies's LPCN Position: Q1 2026 in Review

Renaissance Technologies increased its Lipocine (LPCN) stake by 2.9% in Q1 2026, buying an estimated $9.58K and bringing the position to 38,497 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2784.

Renaissance Technologies first reported a position in LPCN in Q1 2015 and has held it in 33 quarters since. The position peaked at $2.84M in Q3 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

Renaissance Technologies held 38,497 shares of Lipocine worth $308K as of Q1 2026.
Renaissance Technologies bought 1,100 Lipocine shares in Q1 2026, an estimated $9.58K.
Lipocine made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2784 holding.
Renaissance Technologies first reported a position in Lipocine in Q1 2015 and has held it in 33 quarters since.
Renaissance Technologies's Lipocine position peaked at $2.84M in Q3 2015.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.